Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot single-blind trial of candesartan to prevent vincristine-induced peripheral neuropathy in B-cell lymphoma
2017-000585-30Phase 2Terminated
- Sponsor
- CHU de Limoges
- Start
- Oct 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of candesartan in peripheral neuropathy and B-cell non-Hodgkin lymphoma (B-NHL) (2 arms), sponsored by CHU de Limoges. Primary endpoints: Change in Total Neuropathy Score (TNSc) from baseline to week 9 (V3) and Change in Total Neuropathy Score (TNSc) from baseline to later visits (V3 and V4). Started Oct 2017; status: terminated.
02
Drugs
candesartan
03
Conditions
peripheral neuropathyB-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on 2017-000585-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000585-30.